- Query in any language with multilingual search
- Access EUR-Lex and EU Commission case law
- See relevant paragraphs highlighted instantly
Similar Documents
Explore similar documents to your case.We Found Similar Cases for You
Case T-347/18: Action brought on 1st of June 2018 — Laboratoire Pareva and Biotech3D v Commission
ECLI:EU:UNKNOWN:62018TN0347
62018TN0347
With us you find everything. Try it now!
I imagine what I want to write in my case, I write it in the search engine and I get exactly what I wanted. Thank you!
Valentina R., lawyer
(Case T-347/18)
Language of the case: English
Parties
Applicants: Laboratoire Pareva (Saint Martin de Crau, France) and Biotech3D Ltd & Co. KG (Gampern, Austria) (represented by: K. Van Maldegem and S. Englebert, lawyers)
Defendant: European Commission
Form of order sought
—declare the application admissible and well-founded;
—annul the European Commission’s Implementing Regulation (EU) 2018/613 (1) of 20 April 2018 approving PHMB (1415; 4.7) as an existing active substance for use in biocidal products of product-types 2 and 4 under Regulation 528/2012 (2) (the ‘Contested Act’); and
—order the defendant to pay the costs of these proceedings.
Pleas in law and main arguments
In support of the action, the applicants rely on three pleas in law which are in essence identical or similar to those relied on in Case T-337/18, Laboratoire Pareva v Commission.
(1) Commission Implementing Regulation (EU) 2018/613 of 20 April 2018 approving PHMB (1415; 4.7) as an existing active substance for use in biocidal products of product-types 2 and 4 (OJ 2018, L 102, p. 1)
(2) Regulation (EU) No 528/2012 of the European Parliament and of the Council of 22 May 2012 concerning the making available on the market and use of biocidal products (OJ 2012, L 167, p. 1)